0
Editor's Correspondence |

Safety of Statins (Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors): Different Mechanisms of Metabolism and Drug Transport May Have Clinical Relevance—Reply

Michael B. Bottorff, PharmD; Philip Hansten, PharmD
Arch Intern Med. 2001;161(7):1012-1013. doi:.
Text Size: A A A
Published online

Extract

In reply

We appreciate the opportunity to respond to the insightful comments by Dr Vormfelde regarding pharmacokinetics and drug interactions with the statins. With regard to cerivastatin, both the CYP3A4 and CYP2C8 pathways contribute to its metabolism and elimination. Since the submission of the original manuscript, the effects of CYP3A4 inhibition by itraconazole on cerivastatin pharmacokinetics revealed an insignificant increase in cerivastatin acid area under the curve (AUC) of 15%; however, an increase in cerivastatin lactone AUC of 2.6-fold was observed.1 The increase in AUC is more pronounced with coadministration of itraconazole and other CYP3A4-metabolized statins, leading to the conclusion that the CYP3A4 pathway is less important than the CYP2C8 pathway for cerivastatin elimination. Although few drugs are known substrates or inhibitors in the CYP2C8 pathway, unknown or future CYP2C8 inhibitors may have a pronounced effect on cerivastatin pharmacokinetics and increase the likelihood for myopathy. Tranilast, an inhibitor of growth factors released after angioplasty,2 is a known CYP2C9 inhibitor and has recently been identified as a potent CYP2C8 inhibitor as well, causing myopathy in patients receiving cerivastatin (David J. Kazierad, PharmD, oral communication, SmithKline Beecham Pharmaceuticals, Philadelphia, Pa, July 23, 2000). Also, the concurrent use of cerivastatin and gemfibrozil has also been associated with an increased risk of myopathy,3 and this combination is now contraindicated and reflected in the current cerivastatin package insert. Thus, cerivastatin may be less susceptible than some statins to drug interactions involving CYP3A4; however, important interactions with both CYP2C8 inhibition and gemfibrozil (mechanisms unknown) must be remembered.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

April 9, 2001
Michael B. Bottorff, PharmD; Philip Hansten, PharmD
Arch Intern Med. 2001;161(7):1012-1013. doi:.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Scenario

Users' Guides to the Medical Literature
Statin Dosing and LDL Levels

brightcove.createExperiences();